Dietary Salt in Rheumatoid Arthritis

N/A Completed NCT03649178

Condition	Rheumatoid Arthritis
Phase	N/A
Sponsor	Vanderbilt University Medical Center
Status	Completed
Enrollment	18 participants
Interventions	salt
Start date	Jan 2, 2020
Completion date	Sep 30, 2024
Results posted	Oct 24, 2025

Summary

In this study investigators propose to address the following hypotheses: 1) Reduction in dietary sodium will decrease inflammation in patients with rheumatoid arthritis (RA). 2) Reduction in dietary sodium will decrease blood pressure in patients with RA. 3) Reduction in dietary sodium will decrease tissue sodium in patients with RA.

Change in Tissue Sodium

2 scans, one at end of week 8, and one at end of week 20 · mmol/L

High Sodium Diet	17.1 ± 5.1 mmol/L
Low Sodium Diet	16.7 ± 8.2 mmol/L

p-value	0.55

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский